Genentech and Roche announced the initiation of three large phase 3 clinical trials evaluating the Port Delivery System with ranibizumab to treat wet age-related macular degeneration and faricimab to treat diabetic macular edema, according to company correspondence.
The Port Delivery System is a refillable eye implant that continuously releases a formulation of ranibizumab over a period of several months. The delivery system will be evaluated in the phase 3 Archway study, the first phase 3 trial with a device used for the sustained delivery of an anti-VEGF therapy. The trial (Read more...)
Uncategorized